Feb 8 (Reuters) - Theratechnologies Inc TH.TO
* Theratechnologies announces financial results for fiscal year 2016
* Q4 revenue C$10.38 million versus I/B/E/S view c$9.6 million
* Q4 earnings per share C$0.00
* Theratechnologies Inc - anticipate that FY net sales revenue will be in range of $40 million to $42 million
* Theratechnologies -"we are now finalizing our plans for launch of ibalizumab in United States, which we believe will occur in 2017, if approved" Source text for Eikon: ID:nMKWz4wJta Further company coverage: TH.TO